Sanford C. Bernstein initiated coverage on shares of agilon health (NYSE:AGL – Free Report) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a market perform rating and a $2.50 price target on the stock.
AGL has been the topic of several other research reports. Citigroup decreased their target price on agilon health from $2.50 to $1.75 and set a “sell” rating on the stock in a research note on Wednesday, November 13th. Evercore ISI cut their price target on shares of agilon health from $7.00 to $4.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 8th. Stifel Nicolaus dropped their price objective on shares of agilon health from $7.00 to $2.00 and set a “hold” rating for the company in a report on Tuesday, November 12th. JMP Securities downgraded shares of agilon health from an “outperform” rating to a “market perform” rating in a research note on Monday, November 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price target on shares of agilon health in a research report on Tuesday, November 19th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, agilon health currently has a consensus rating of “Hold” and a consensus target price of $4.38.
View Our Latest Research Report on AGL
agilon health Trading Up 1.4 %
agilon health (NYSE:AGL – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.19). agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. The company had revenue of $1.45 billion during the quarter, compared to analyst estimates of $1.47 billion. During the same quarter last year, the business posted ($0.06) EPS. On average, analysts predict that agilon health will post -0.52 EPS for the current year.
Insider Buying and Selling
In other news, Director John William Wulf bought 45,000 shares of agilon health stock in a transaction dated Thursday, December 5th. The stock was acquired at an average cost of $2.18 per share, with a total value of $98,100.00. Following the acquisition, the director now owns 206,133 shares of the company’s stock, valued at approximately $449,369.94. This trade represents a 27.93 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Karen Mcloughlin purchased 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $2.20 per share, for a total transaction of $55,000.00. Following the purchase, the director now directly owns 73,166 shares in the company, valued at $160,965.20. The trade was a 51.90 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 90,000 shares of company stock worth $198,100 over the last 90 days. 3.20% of the stock is owned by insiders.
Institutional Investors Weigh In On agilon health
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of agilon health by 3.0% in the 3rd quarter. State Street Corp now owns 7,449,706 shares of the company’s stock valued at $29,277,000 after acquiring an additional 215,733 shares during the period. Geode Capital Management LLC grew its position in agilon health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company’s stock worth $27,097,000 after purchasing an additional 84,889 shares during the last quarter. Citigroup Inc. increased its stake in agilon health by 2,251.5% in the third quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock valued at $7,971,000 after purchasing an additional 1,941,993 shares during the period. AQR Capital Management LLC raised its holdings in shares of agilon health by 3,338.5% in the second quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock valued at $8,871,000 after buying an additional 1,316,990 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of agilon health by 21.2% during the third quarter. Barclays PLC now owns 1,228,952 shares of the company’s stock worth $4,830,000 after buying an additional 214,830 shares during the period.
agilon health Company Profile
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Further Reading
- Five stocks we like better than agilon health
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Why Invest in High-Yield Dividend Stocks?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How to Effectively Use the MarketBeat Ratings Screener
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.